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Abstract
AIM: To investigate the expression of genes involved 
in the gemcitabine-induced cytotoxicity in human 
pancreatic cancer cells.  
METHODS: A human pancreatic cancer cell l ine, 
PANC-1, was cultured. 1 x 104 PANC-1 cells were plated 
in 96-well microtiter plates. After being incubated for 24 h, 
gemcitabine was added to the medium at concentrations 
ranging 2.5 -1 000 mg/L. The AlamarBlue dye method 
was used for cell growth analysis. DNA fragmentation 
was quantitatively assayed using a DNA fragmentation 
enzyme-linked immunosorbent assay (ELISA) kit. PAP  
and TP53INP1  mRNA expression was determined using 
the reverse transcription-polymerase chain reaction with 
semi-quantitative analysis. The expression of GSK-3β and 
phospho-GSK-3β proteins was examined with Western 
blot analysis.
RESULTS: The IC50 for the drug after a 48-h exposure 
to gemcitabine was 16 mg/L. The growth of PANC-1 
cells was inhibited by gemcitabine in a concentration-
dependent manner (P < 0.0001) and the cell growth was 
also inhibited throughout the time course (P < 0.0001). 
The DNA fragmentation rate in the gemcitabine-treated 
group at 48 h was 44.7 %, whereas it was 25.3 % in 
the untreated group. The PAP  mRNA expression was 
decreased after being treated with gemcitabine, whereas 
the TP53INP1  mRNA was increased by the gemcitabine 
treatment. Western blot analysis showed that phospho- 
GSK-3βser9 was induced by the gemcitabine treatment.
CONCLUSION: Gemcitabine suppresses PANC-1 
cell proliferation and induces apoptosis. Apoptosis is 
considered to be associated with the inhibition of PAP 
and GSK-3β, and the activation of TP53INP1  and pospho-
GSK-3βser9.
© 2006 The WJG Press. All rights reserved.
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Pancreatic cancer is the fifth most common cause of  
cancer death in Japan[1]. It is estimated that there are 
20000 cases every year, which is similar to the number 
of  deaths from this disease. The reasons for its very high 
mortality rate include the lack of  early diagnosis, a low 
resectability at the time of  initial diagnosis, and the rapid 
recurrence after resection. Surgery is rarely a curative 
option in pancreatic cancers because of  local extension 
and metastasis. Chemotherapy for advanced pancreatic 
cancer is palliative. The use of  5-FU in combination 
with radiation in the locally advanced setting has been 
shown to enhance survival. In a randomized trial between 
gemcitabine and 5-FU, gemcitabine showed significantly 
better results in terms of  the clinical benefit effect and 
survival[2].
Gemcitabine (2 ′ , 2 ′-dif luorodeoxycit idine) is a 
nucleoside analogue well known for its antitumor 
activity in several solid tumors[3]. It is one of  the drugs 
effective for pancreatic cancers in the clinical treatment[4]. 
Various general mechanisms of  gemcitabine have been 
described[5-7]. A primary mechanism of  gemcitabine 
is the blocking of  DNA synthesis by inhibiting DNA 
polymerase activity[8]. Gemcitabine itself  is not active until 
it enters the cells. Its intracellular transport is mediated 
by facilitated diffusion[9]. Intracellularly, gemcitabine is 
phosphorylated to its active metabolites by deoxycitidine 
k inase to d i f luorodeoxyci t id ine monophosphate 
(dfdCMP), difluorodeoxycitidine diphosphate (dfdCDP) 
and difluorodeoxycitidine triphosphate (dfdCTP). All 
three of  the metabolites interfere at different steps in the 
processing of  DNA. The dfdCTP is incorporated into 
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A BDNA and as such can obstruct DNA replication and 
repair. The dfdCTP can also be incorporated into RNA 
and can inhibit CTP-synthetase. The dfdCMP can also 
inhibit dCMP-deaminase. The dfdCDP is an inhibitor 
of  ribonucleotide reductase, and its action was shown to 
lead to the depletion of  the DNA precursor pool, dNTP. 
Inhibition of  DNA synthesis leads to growth inhibition 
or cell death. In previous studies, gemcitabine has been 
shown to play a major role in the apoptosis of  certain 
tumor cell lines[10-12]. There are several pathways that 
relate to gemcitabine-induced apoptosis. Nicole et al[13] 
reported that gemcitabine-mediated apoptosis is caspase-
dependent in pancreatic cancers; Jones et al[14] showed 
that gemcitabine-induced apoptosis is achieved through 
the blocking of  NF-kB in non-small cell lung cancer cells 
(NSCLC). In addition, gemcitabine-induced apoptosis 
is also related to signal-regulated kinase (ERK), Akt, 
Bcl-2 and p38 mitogen-activated protein kinase (MAPK) 
pathways[15-17]. Achiwa et al[18] indicated that the increase in 
human equilibrate nucleoside transport (hENT) expression 
is a determinant of  gemcitabine sensitivity in NSCLC 
cells. However, the molecular mechanism of  gemcitabine-
induced apoptosis has not been fully elucidated. 
Pancreatitis-associated protein (PAP) is a secretory 
protein of  pancreatic acinar cells. It is almost absent 
in the normal pancreas, but is induced in acute and 
chronic pancreatitis. We have reported the expression of  
PAP mRNA in cancer tissues and have measured PAP 
levels in the sera and pancreatic juice of  patients with 
gastrointestinal cancers[19-21]. We found that serum PAP 
levels were increased in 40% of  patients with pancreatic 
cancer. We also reported that PAP levels in endoscopically 
aspirated pancreatic juice were positive in 55% of  
pancreatic cancers. PAP levels were signifi cantly higher in 
both the serum and pancreatic juice in cases of  pancreatic 
cancer, compared to chronic pancreatitis. Cytokines such 
as tumor necrosis factor-α, interferon-γ, and interleukin-6 
induce PAP mRNA expression in the pancreatic acinar 
AR4-2J cell line. We found that the enhanced expression 
of  PAP in pancreatic adenocarcinoma is caused by both 
ectopic expression in cancer cells and induction in acinar 
cells[22]. 
TP53INP1 [23] was previously called stress-induced 
protein (SIP)[24] or p53-dependent inducible nuclear 
protein (p53DINP1)[25]. TP53INP1 is strongly induced in 
acinar cells during acute pancreatitis in mice, and is also 
overexpressed in response to various stresses in vitro. 
TP53INP1 gene expression is wild-type p53-dependent[26]. 
There is a functional p53-response element within the 
promoter region of  the TP53INP1 gene, and TP53INP1 
mRNA expression is activated in cells expressing wild-
type p53 in response to various stresses. One of  the major 
functions of  TP53INP1 is promoting cellular apoptosis. 
Glycogen synthase kinase 3β (GSK-3β) is a multifunctional 
serine/threonine kinase mediating various cellular signaling 
pathways. The particular pathway depends on its substrates 
for phosphorylation[27]. Since GSK-3β is also an important 
mediator of  an apoptotic signal, it is plausible that the 
GSK-3β deregulation observed in cancer cells confers 
resistance to chemotherapy, which is a major cause of  
treatment failure in human cancers[28]. 
In this study we investigated the effect of  gemcitabine 
on the PANC-1 cells in terms of  apoptosis-related factors.
MATERIALS AND METHODS
Cell culture and gemcitabine treatment
A human pancreatic cancer cell line, PANC-1, obtained 
from the American Type Culture Collection (ATCC, 
MD, USA), was maintained in Dulbecco’s modified 
Eagle's medium supplemented with 100 mL/L fetal 
calf  serum, penicillin, and kanamycin at 37℃ in a 50 
mL/L CO2, 950 mL/L air atmosphere. Gemcitabine (Eli-
Lilly Japan, Kobe, Japan) at a concentration of  50 mg/mL 
was dissolved in the serum free culture medium and stored 
at -20 ℃ in the freezer. The concentration range of  the 
treatment was from 2.5 mg /L to 1 000 mg/L. 
Cell growth evaluation
The Alamarblue dye method was used for cell growth 
analysis. The 1×104 cells were plated in 96-well microtiter 
plates. After being incubated for 24 h, gemcitabine was 
added to the medium. Twenty μL of  AlamarBlue dye 
solution (Iwaki Glassware, Inc., Tokyo, Japan) was added 
to wells containing 200 μL of  medium at the time 12, 
24, 48, and 72 h. After being incubated for 3 h, the cell 
growth was evaluated as the absorbance (A) using a 
spectrophotometer (Dai-Nippon Pharmaceutical Co., 
Osaka, Japan). An excitation wavelength of  540 nm was 
used, and the emission was read at 620 nm. The color 
of  AlamarBlue stock is violet, and changes to red when 
oxidized. Each treatment was applied to 6 wells, and the 
experiments were repeated 3 times.
DNA fragmentation assay
DNA fragmentation was quantitatively assayed using a 
DNA fragmentation enzyme-linked immunosorbent assay 
(ELISA) kit (Boehringer Mannheim GmbH, Mannheim, 
Germany) according to the protocol. Cells were cultured 
in flat-bottom, 96-well microplates. After incubation in 
gemcitabine-supplemented media for 24 h, the cells were 
detached from the wells. The cells were lysed with lysis 
buffer, and the lysate was processed for streptavidin-
coated microtiter plates. After incubation with biotin-
labeled antihistone antibody and peroxidase-labeled anti-
DNA antibody, the amount of  fragmented DNA was 
determined using 2, 2′-azino-bis-3-ethylbenzthiazoline-
sulfonate (ABTS) as a substrate. The plates were read on a 
Labsystems integrated EIA (Dai-Nippon Pharmaceutical 
Co., Osaka, Japan) at wavelengths of  540 nm and 620 
nm. Each treatment was added to duplicate wells, and the 
experiment repeated 3 times.
Total RNA was extracted from pancreatic cancer cells 
using a SV Total RNA Isolation system kit (Promega, 
Madison, WI, USA). RNA concentrations were determined 
with spectrophotometry. RT was performed using a 
PowerScriptTM Reverse Transcriptase kit (Clontech 
Laboratories, Inc., Palo Alto, CA, USA). First strand cDNA 
was synthesized from 8 μg of  total RNA at 65 ℃ for 5 
min after RT; the reverse transcriptase was inactivated 
by incubating at 42 ℃ for 60 min and the reaction was 
terminated by heating at 70 ℃ for 25 min. Then, cycles 
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of  amplification were performed on a DNA thermal 
cycler (Perkin Elmer Cetus, Inc., Norwalk, CT, USA) 
as follows: PAP primers were denatured at 91℃ for 
60 sec, annealed at 54 ℃ for 60 sec, and polymerized 
at 72 ℃ for 45 sec. Then, extension was performed at 
72 ℃ for 10 min. TP53INP1 primers were denatured 
at 94 ℃ for 50 sec, annealed at 62 ℃ for 40 sec, and 
polymerized at 72 ℃ for 50 sec. The extension was 
performed at 72 ℃ for 10 min. The PAP primer pairs 
were sense: 5’-CTCCTGATTGCCTCCTCAAG -3’ 
and antisense: 5’-AAACGTACCCTCTCTTTAGG -3’, 
producing a fragment of  441 bp. TP53INP1 mRNA was 
specifi cally amplifi ed with the following primers: sense 5’
-CATCCAGCCAAACTCTCAGTC -3’ and antisense 5’
-GCGACGAAGGCTATTTCTGT -3’. The size of  the 
fragment was 703 base pairs (bp). The GAPDH of  452 bp 
was used as an internal control. Eight-microgram aliquots 
of  the RT-PCR products were subjected to electrophoresis 
on a 20 g/L agarose gel and visualized with SYBR Gold 
(Molecular Probes, Inc., Eugene, OR, USA) at a 1:10000 
dilution in dimethylsulfoxide, and exposed to ultraviolet 
312-nm light. 
Semiquantitative RT-PCR analysis
The gene expression of  PAP and TP53INP1 was semi-
quantitatively analyzed with an image analyzer (ATTO 
Densitograph ver. 3.02, ATTO, Inc., Tokyo, Japan). The 
relative expression intensity was calculated according to 
the following formula: PAP and TP53INP1 mRNA in a 
sample/GAPDH mRNA in a sample.
Western blot analysis
For Western blot analysis, 1×106 PANC-1 cells were lysed 
in a CelLyticTM mammalia tissue lysis/ extraction reagent 
buffer (Sigma-Aldrich, St. Louis, MO, USA). Aliquots were 
boiled for 5 minutes with Laemli buffer, resolved on a 
125 g/L SDS-PAGE gel and eletrophoretically transferred 
to nitrocellulose membrane (Amersham, Buckingham, 
UK). Membranes were blocked for 1 h in TBS containing 
50 g/L dry milk and 1 g/L Tween 20. Membranes were 
then incubated with either anti-rabbit phospho-GSK-3β 
(ser9) polyclonal antibody (Cell Signaling Technology, Inc. 
Beverly, MA, USA) or anti-mouse GSK-3β monoclonal 
antibody (BD Transduction Laboratories, Lexington, KY, 
USA) for one night at 4 ℃. After incubation with anti-
rabbit or anti-mouse IgG second antibody labeled with 
peroxidase, the membranes were visualized with an ATTO 
image analyzer. 
Statistical analysis
Experimental results were expressed as the mean ± SE. 
The difference between the means was evaluated with the 
Mann-Whitney U test. P < 0.05 was considered statistically 
significant. The statistical analysis was performed using 
StatView-5.0 (SAS Institute Inc. Tokyo, Japan).
RESULTS
Gemcitabine inhibited cell growth 
The median 50% inhibitory concentration (IC50) of  gem-
citabine after a 48-h exposure was 16 mg/L (Figure 1). We 
also measured the effect of  4, 16 and 64 mg/L gemcita-
bine at 12, 24, 36, and 48 h. The growth of  PANC-1 cells 
was inhibited by gemcitabine in a concentration-dependent 
manner (P < 0.0001, Figure 2) and cell growth was also in-
hibited throughout the time course (P < 0.0001).
Gemcitabine induced apoptosis
1×104 PANC-1 cells were cultured in fl at-bottom, 96-well 
microplates. After incubation in gemcitabine-supplemented 
media for 24 h, a DNA fragmentation assay was perfor-
med. The concentration of  gemcitabine used in the DNA 
fragmentation assay was 16 mg/L. The DNA fragmen-
tation rate in the gemcitabine-treated group was 44.7%, 
whereas the fragmentation rate in the untreated group 
was 25.3%. The fragmentation in the gemcitabine treated 
group was signifi cantly higher than that in the untreated 
group (P = 0.0157).
Expression of PAP, TP53INP1 mRNA
We exposed the PANC-1 cells to 4, 16 and 64 mg/L 
gemcitabine for 48 h. The expression of  PAP and 
TP53INP1 mRNA was assessed using RT-PCR. The 
PAP mRNA expression was decreased after being treated 
with gemcitabine, and disappeared after being treated 
with 16 mg/L gemcitabine. The semiquantitative analysis 









































Figure 2 Inhibitory effect of gemcitabine on the growth of PANC-1 cells. 
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cells to be signifi cantly lower than that of  the untreated 
cells (P = 0.0165, Figure 3). The TP53INP1 mRNA was 
increased after exposure to gemcitabine. The intensity of  
the cells treated with 4, 16 and 64 mg/L gemcitabine was 2 
times, 8.5 times and 14.6 times higher than in the untreated 
cells, respectively. The increasing density of  TP53INP1 
mRNA was concentration-dependent. The P value of  
the interrelation of  the untreated group to the 4 mg/L 
gemcitabine-treated group, 16 mg/L gemcitabine-treated 
group and 64mg/L gemcitabine-treated group were 0.0015, 
0.0009 and 0.0352, respectively.
Expression of phospho-GSK-3β and GSK-3β proteins 
The PANC-1 cell line showed no detectable phospho- 
GSK-3βser9 in Western blotting analysis with a phospho-
specifi c antibody, indicating GSK-3β activity in this cell 
line (Figure 4). On the other hand, phospho- GSK-3βser9 
was induced after 4 mg/L gemcitabine treatment, and 
gradually increased with the 16 and 64 mg/L gemcitabine 
treatment. There was no signifi cant difference in GSK-
3β expression between the gemcitabine-treated and 
untreated groups.
DISCUSSION
Gemcitabine is a nucleotide analog that is converted to 
its triphosphate active form in cells and is subsequently 
incorporated into DNA to terminate strand elongation[13-17]. 
It shows a favorable clinical outcome in the treatment 
of  pancreatic cancer and non-small cell lung cancer[14,18]. 
However, there have been few published in vitro analyses 
about gemcitabine. We therefore attempted to investigate 
the genes involved in the gemcitabine-induced cytotoxicity 
of  pancreatic cancer cells. In the present study we showed 
that gemcitabine induced changes in expression of  
apoptosis-related genes in PANC-1 cells. The expression 
of  anti-apoptotic pancreatitis-associated protein (PAP) 
was down-regulated, whereas the pro-apoptotic TP53INP1 
and p-GSK-3β were up-regulated after being treated with 
gemcitabine.
Apoptosis is believed to play an important role in 
tumors, and both pro- and anti-apoptotic factors are 
simultaneously activated in tumor development and 
progression. In this study, we showed that PAP expression 
was significantly decreased in the gemcitabine-induced 
anti-tumor process. The growth of  human pancreatic 
cancer may require the up-regulation of  PAP expression, 
which would suppress the apoptosis of  cancer cells[19]. 
PAP is one of  the effectors of  antiapoptosis induced by 
tumor necrosis factor-α through NF-κB and MAP kinases 
in pancreatic acinar cells[29]. It was demonstrated that 
the activation status of  the NF-κB, Akt and MAP kinase 
signaling pathways is often associated with anti-apoptotic 
signal transduction that is linked to chemotherapeutic 
agents[16]. NF-κB plays an important role in oncogenesis 
and promotes cellular resistance to anticancer therapy. 
Bandala et al [30] showed that gemcitabine treatment 
increased the activity of  NF-κB, and Alexader et al[31] 
showed that the induction of  NF-κB by gemcitabine 
was dose-dependent in five pancreatic cancer cell lines. 
In addition, gemcitabine specifically activates p38 MAP 
kinases in the human pancreatic cancer cell lines, PK-1 and 
PCI43[16]. Taken together, these findings confirmed that 























































Figure 3 PAP  mRNA expression after gemcitabine treatment.





Figure 4 Effect of gemcitabine treatment on GSK-3β expression.
Untreated              4                     16                     64
C (Gemcitabine)/(mg/L)
dose-dependent manner.
Apoptosis is one of  the major consequences of  
chemotherapy against malignancies. It is now established 
that the tumor suppressor p53 inhibits cell growth 
through the activation of  cell cycle arrest and apoptosis. 
TP53INP1 is a gene that is activated by wild type p53. It 
cooperates with HIPK2 to promote p53 phosphorylation 
at ser 46, and then induces apoptosis-inducing protein 
activation[25, 26]. In our conditions, we showed TP53INP1 
was up-regulated by gemcitabine treatment from 4 mg/L 
to 64 mg/L, in a dose-dependent manner. TP53INP1 
may be involved in gemcitabine-mediated apoptosis. 
The precise mechanism of  the TP53INP1 increase after 
gemcitabine treatment is unclear. It has been shown that 
phosphorylation of  the NH2-terminal residues of  p53 
mediates its stabilization and nuclear accumulation after 
anticancer drug treatment[28].
B e u r e l e t a l [ 2 8 ] h a s r e p o r t e d t h a t G S K - 3β i s 
hyperphosphorylated on serine 9 in human hepatoma 
cell lines as well as in human and murine tumoral livers. 
We examined the impact of  gemcitabine on GSK-3β 
activity in PANC-1 cells by measuring the phosphorylation 
level of  GSK-3β at serine 9 as an indicator of  GSK-
3β inactivation. GSK-3β can act as a positive or negative 
physiological regulator of  the p53 protein. During 
endoplasmic reticulum stress, p53 is inhibited through a 
mechanism involving its phosphorylation at ser 315 and 
ser 376 by GSK-3β. On the other hand, GSK-3β plays 
a crucial role in cell survival mediated by nuclear factor-
kappaB (NF-κB) signaling. Phospho- GSK-3βser9 is an 
inactive form in normal tissues that suggests the regulation 
of  the balanced expression of  the active and inactive 
forms of  this kinase. In our data, phospho- GSK-3βser9 was 
induced by gemcitabine treatment, indicating that GSK-
3βgradually became inactive in the gemcitabine-treated 
cells. Our results are similar to those of  Beurel et al[28], 
who showed that GSK-3βser9 phosphorylation by lithium 
treatment on tumor cells conferred resistance to anticancer 
therapy.
In conclusion, gemcitabine decreases cell proliferation 
of  a human pancreatic cancer cell line, PANC-1, and 
promotes cellular apoptosis. The antiapoptotic gene, PAP, 
is down-regulated by gemcitabine treatment, whereas the 
pro-apoptotic TP53INP1 gene and GSK-3βser9 protein are 
up-regulated. Gemcitabine can induce apoptosis in cancer 
cells through GSK-3β and PAP inhibition, and TP53INP1 
and GSK-3βser9 activation. 
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